Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat
暂无分享,去创建一个
[1] S. Amir,et al. Global Depletion of Dopamine Using Intracerebroventricular 6-Hydroxydopamine Injection Disrupts Normal Circadian Wheel-Running Patterns and PERIOD2 Expression in the Rat Forebrain , 2011, Journal of Molecular Neuroscience.
[2] M. Contin,et al. Pharmacokinetics of levodopa , 2010, Journal of Neurology.
[3] P. Jenner,et al. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset. , 2010, European journal of pharmacology.
[4] B. Bruguerolle,et al. EFFECTS OF L-DOPA ON CIRCADIAN RHYTHMS OF 6-OHDA STRIATAL LESIONED RATS: A RADIOTELEMETRIC STUDY , 2010, Chronobiology international.
[5] V. Pillay,et al. Levodopa delivery systems: advancements in delivery of the gold standard , 2010, Expert opinion on drug delivery.
[6] S. Dunnett,et al. Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model , 2009, Brain Research Bulletin.
[7] M. Yliperttula,et al. Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[8] P. Jenner,et al. Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398 , 2008, Journal of Neural Transmission.
[9] W. Danysz,et al. Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model , 2007, Behavioural Brain Research.
[10] P. Jenner,et al. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats , 2007, Brain Research.
[11] M. Cenci,et al. The “motor complication syndrome” in rats with 6-OHDA lesions treated chronically with l-DOPA: Relation to dose and route of administration , 2007, Behavioural Brain Research.
[12] M. Cenci,et al. Post‐ versus presynaptic plasticity in L‐DOPA‐induced dyskinesia , 2006, Journal of neurochemistry.
[13] P. Jenner,et al. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? , 2006, Experimental Neurology.
[14] P. Jenner,et al. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6‐hydroxydopamine lesioned rat without sensitizing motor behaviours , 2005, The European journal of neuroscience.
[15] W. Poewe,et al. Effects of pulsatile l-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy) , 2004, Neurobiology of Disease.
[16] T. Suda,et al. Amantadine increases l-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats , 2003, Brain Research.
[17] M. Matsunaga,et al. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. , 2003, The Tohoku journal of experimental medicine.
[18] W Birkmayer,et al. The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961. , 2001, Wiener klinische Wochenschrift.
[19] Y. Michotte,et al. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat , 2001, Journal of Neural Transmission.
[20] P. Jenner,et al. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD‐1015, does not inhibit l‐DOPA‐induced circling in unilateral 6‐OHDA‐lesioned‐rats , 2001, The European journal of neuroscience.
[21] BERNARD BRUGUEROLLE,et al. Time‐dependent Striatal Dopamine Depletion after Injection of 6‐Hydroxydopamine in the Rat. Comparison of Single Bilateral and Double Bilateral Lesions , 1999, The Journal of pharmacy and pharmacology.
[22] W Birkmayer,et al. The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism. , 1998, Parkinsonism & related disorders.
[23] A. Swann,et al. Diurnal differences in rat's motor response to amphetamine. , 1998, European journal of pharmacology.
[24] A. Swann,et al. Time-Dependent Differences in the Rat’s Motor Response to Amphetamine , 1998, Pharmacology Biochemistry and Behavior.
[25] J. Huston,et al. Early L-DOPA treatment initially retards but later enhances dopamine receptor supersensitivity following unilateral dopamine denervation , 1994, Brain Research.
[26] E. Montgomery. Pharmacokinetics and pharmacodynamics of levodopa , 1992, Neurology.
[27] R. Carey. Chronicl-DOPA treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance , 1991, Brain Research.
[28] W. Haefely,et al. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. , 1987, European neurology.
[29] J. Nutt,et al. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients , 1986, Neurology.
[30] Charles Watson,et al. Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight , 1985, Journal of Neuroscience Methods.
[31] A. Björklund,et al. Functional Activity of Substantia Nigra Grafts Reinnervating the Striatum: Neurotransmitter Metabolism and [14C]2‐Deoxy‐d‐glucose Autoradiography , 1982, Journal of neurochemistry.
[32] J. Reid,et al. COMPARISON OF LEVODOPA WITH CARBIDOPA OR BENSERAZIDE IN PARKINSONISM , 1976, The Lancet.
[33] A. Pletscher,et al. Effect of various decarboxylase inhibitors on the cerebral metabolism of dihydroxyphenylalanine , 1969, The Journal of pharmacy and pharmacology.
[34] U. Ungerstedt,et al. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. , 1968, European journal of pharmacology.
[35] A. Sjoerdsma,et al. Reduction of the central effects of tryptophan by a decarboxylase inhibitor , 1964, Clinical pharmacology and therapeutics.
[36] P. Holtz,et al. [Effect of reserpine, iproniazid & biogenic amines on evipan narcosis]. , 1957, Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie.